Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12

Nucleic Acid Therapeutics

Volumn 23, Issue 3, 2013, Pages 175-187

  Bhattacharjee, Gourab ^a   Revenko, Alexey S ^a   Crosby, Jeffrey R ^a   May, Chris ^a   Gao, Dacao ^a   Zhao, Chenguang ^a   Monia, Brett P ^a   MacLeod, A Robert ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA; PLASMA KALLIKREIN; PREKALLIKREIN;

ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; KALLIKREIN KININ SYSTEM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION;

ANGIOEDEMAS, HEREDITARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD COAGULATION; CAPILLARY PERMEABILITY; COMPLEMENT C1 INHIBITOR PROTEIN; DISEASE MODELS, ANIMAL; FACTOR VII; FACTOR XI; FACTOR XII; HUMANS; INJECTIONS, SUBCUTANEOUS; KININS; MALE; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; PLASMA KALLIKREIN; PREKALLIKREIN;

EID: 84878243943     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0417     Document Type: Article

References (52)

1. Adjei, A.A., Dy, G.K., Erlichman, C., Reid, J.M., Sloan, J.A., Pitot, H.C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Atherton, P.J., et al. (2003). A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. 9:115-123.
2. Agostoni, A., Aygoren-Pursun, E., Binkley, K.E., Blanch, A., Bork, K., Bouillet, L., Bucher, C., Castaldo, A.J., Cicardi, M., Davis, A.E., et al. (2004). Hereditary and acquired angioede-ma: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114:S51-131.
3. Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M., and Bennett, C.F. (1997). 2¢-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272:11994-12000.
4. Bell, D.A., Hooper, A.J., and Burnett, J.R. (2011). Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin. Investig. Drugs 20:265-272.
5. Bennett, C.F., and Swayze, E.E. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
6. Bossi, F., Fischetti, F., Regoli, D., Durigutto, P., Frossi, B., Gobeil, F., Jr., Ghebrehiwet, B., Peerschke, E.I., Cicardi, M., and Tedesco, F. (2009). Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J. Allergy Clin. Immunol. 124:1303-1310, e1304.
7. Camargo, A.C., Ianzer, D., Guerreiro, J.R., and Serrano, S.M. (2011). Bradykinin-potentiating peptides: Beyond captopril. Toxicon doi: 10.1016/j.toxicon.2011.07.013.
8. Cugno, M., Castelli, R., and Cicardi, M. (2008). Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun. Rev. 8:156-159.
9. Cugno, M., Cicardi, M., Bottasso, B., Coppola, R., Paonessa, R., Mannucci, P.M., and Agostoni, A. (1997). Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89: 3213-3218.
10. Cugno, M., Zanichelli, A., Bellatorre, A.G., Griffini, S., and Cicardi, M. (2009a). Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 64:254-257.
11. Cugno, M., Zanichelli, A., Foieni, F., Caccia, S., and Cicardi, M. (2009b). C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol. Med. 15:69-78.
12. Davis, A.E., 3rd. (2005). The pathophysiology of hereditary an-gioedema. Clin. Immunol. 114:3-9.
13. Endler, G., Marsik, C., Jilma, B., Schickbauer, T., Quehenberger, P., and Mannhalter, C. (2007). Evidence of a U-shaped association between factor 12 activity and overall survival. J. Thromb. Haemost. 5:1143-1148.
14. Fidias, P., Pennell, N.A., Boral, A.L., Shapiro, G.I., Skarin, A.T., Eder, J.P., Jr., Kwoh, T.J., Geary, R.S., Johnson, B.E., Lynch, T.J., et al. (2009). Phase 1 study of the c-raf-1 antisense oligo-nucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer. J. Thorac. Oncol. 4:1156-1162.
15. Fields, T., Ghebrehiwet, B., and Kaplan, A.P. (1983). Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of ''spontaneous'' formation of bradykinin. J. Allergy Clin. Immunol. 72:54-60.
16. Forbes, C.D., Pensky, J., and Ratnoff, O.D. (1970). Inhibition of activated Hageman factor and activated plasma thrombo-plastin antecedent by purified serum C1 inactivator. J. Lab. Clin. Med. 76:809-815.
17. Forte, A., Cipollaro, M., Cascino, A., and Galderisi, U. (2005). Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases. Curr. Drug Targets 6:21-29.
18. Frank, M.M. (2008). 8. Hereditary angioedema. J. Allergy Clin. Immunol. 121:S398-401; quiz S419.
19. Gailani, D., and Renne, T. (2007). Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 27:2507-2513.
20. Gao, B.B., Clermont, A., Rook, S., Fonda, S.J., Srinivasan, V.J., Wojtkowski, M., Fujimoto, J.G., Avery, R.L., Arrigg, P.G., Bursell, S.E., et al. (2007). Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 13:181-188.
21. Geary, R.S., Bradley, J.D., Watanabe, T., Kwon, Y., Wedel, M., van Lier, J.J., and VanVliet, A.A. (2006). Lack of pharmacokinetic interaction for ISIS 113715, a 2¢-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin. Pharmacokinet. 45:789-801.
22. Gigli, I., Mason, J.W., Colman, R.W., and Austen, K.F. (1970). Interaction of plasma kallikrein with the C1 inhibitor. J. Immunol. 104:574-581.
23. Girolami, A., Allemand, E., Bertozzi, I., Candeo, N., Marun, S., and Girolami, B. (2010a). Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol. 123:210-214.
24. Girolami, A., Randi, M.L., Gavasso, S., Lombardi, A.M., and Spiezia, F. (2004). The occasional venous thromboses seen in patients with severe (homozygous) F12 deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis 17:139-143.
25. Girolami, A., Scarparo, P., Candeo, N., and Lombardi, A.M. (2010b). Congenital prekallikrein deficiency. Expert Rev. He-matol. 3:685-695.
26. Han, E.D., MacFarlane, R.C., Mulligan, A.N., Scafidi, J., and Davis, A.E., 3rd. (2002). Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 109:1057-1063.
27. Henry, S.P., Geary, R.S., Yu, R., and Levin, A.A. (2001). Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2:1444-1449.
28. Koller, E., Vincent, T.M., Chappell, A., De, S., Manoharan, M., and Bennett, C.F. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39:4795-4807.
29. Koster, T., Rosendaal, F.R., Briet, E., and Vandenbroucke, J.P. (1994). John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br. J. Haematol. 87:422-424.
30. Lamoureux, F., Thomas, C., Yin, M.J., Kuruma, H., Beraldi, E., Fazli, L., Zoubeidi, A., and Gleave, M.E. (2011). Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 71:5838-5849.
31. Lo, S.K., Garcia-Szabo, R.R., and Malik, A.B. (1990). Leukocyte repletion reverses protective effect of neutropenia in throm-bin-induced increase in lung vascular permeability. Am. J. Physiol. 259:H149-155.
32. Lum, H., Andersen, T.T., Siflinger-Birnboim, A., Tiruppathi, C., Goligorsky, M.S., Fenton, J.W., 2nd, and Malik, A.B. (1993). Thrombin receptor peptide inhibits thrombin-induced increase in endothelial permeability by receptor desensitization. J. Cell Biol. 120:1491-1499.
33. Maas, C., Govers-Riemslag, J.W., Bouma, B., Schiks, B., Hazenberg, B.P., Lokhorst, H.M., Hammarstrom, P., ten Cate, H., de Groot, P.G., Bouma, B.N., et al. (2008). Misfolded proteins activate factor 12 in humans, leading to kallikrein formation without initiating coagulation. J. Clin. Invest. 118:3208-3218.
34. Malik, A.B., and Fenton, J.W., 2nd. (1992). Thrombin-mediated increase in vascular endothelial permeability. Semin. Thromb. Hemost. 18:193-199.
35. Nielsen, E.W., Johansen, H.T., Hogasen, K., Wuillemin, W., Hack, C.E., and Mollnes, T.E. (1996). Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand. J. Immunol. 44:185-192.
36. Oschatz, C., Maas, C., Lecher, B., Jansen, T., Bjorkqvist, J., Tra-dler, T., Sedlmeier, R., Burfeind, P., Cichon, S., Hammerschmidt, S., et al. (2011). Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34:258-268.
37. Pappalardo, E., Zingale, L.C., Terlizzi, A., Zanichelli, A., Fol-cioni, A., and Cicardi, M. (2002). Mechanisms of C1-inhibitor deficiency. Immunobiology 205:542-551.
38. Ratnoff, O.D. (1980). A quarter century with Mr. Hageman. Thromb. Haemost. 43:95-98.
39. Ratnoff, O.D., Pensky, J., Ogston, D., and Naff, G.B. (1969). The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C¢1r subcomponent of the first component of complement by serum C¢1 esterase inhibitor. J. Exp. Med. 129:315-331.
40. Renne, T., Pozgajova, M., Gruner, S., Schuh, K., Pauer, H.U., Burfeind, P., Gailani, D., and Nieswandt, B. (2005). Defective thrombus formation in mice lacking coagulation factor 12. J. Exp. Med. 202:271-281.
41. Revenko, A.S., Gao, D., Crosby, J.R., Bhattacharjee, G., Zhao, C., May, C., Gailani, D., Monia, B.P., and Macleod, A.R. (2011). Selective depletion of plasma prekallikrein or coagulation factor 12 inhibits thrombosis in mice without increased risk of bleeding. Blood 118:5302-5311.
42. Samuel, V.T., Choi, C.S., Phillips, T.G., Romanelli, A.J., Geisler, J.G., Bhanot, S., McKay, R., Monia, B., Shutter, J.R., Lindberg, R.A., et al. (2006). Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55:2042-2050.
43. Savage, D.B., Choi, C.S., Samuel, V.T., Liu, Z.X., Zhang, D., Wang, A., Zhang, X.M., Cline, G.W., Yu, X.X., Geisler, J.G., et al. (2006). Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116: 817-824.
44. Schaeffer, R.C., Jr., Gong, F., Bitrick, M.S., Jr., and Smith, T.L. (1993). Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am. J. Physiol. 264:H1798-1809.
45. Schmaier, A.H., and McCrae, K.R. (2007). The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost. 5:2323-2329.
46. Schreiber, A.D., Kaplan, A.P., and Austen, K.F. (1973). Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J. Clin. Invest. 52:1402-1409.
47. Tiruppathi, C., Malik, A.B., Del Vecchio, P.J., Keese, C.R., and Giaever, I. (1992). Electrical method for detection of endo-thelial cell shape change in real time: assessment of endo-thelial barrier function. Proc. Natl. Acad. Sci. U. S. A. 89: 7919-7923.
48. Villalona-Calero, M.A., Ritch, P., Figueroa, J.A., Otterson, G.A., Belt, R., Dow, E., George, S., Leonardo, J., McCachren, S., Miller, G.L., et al. (2004). A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10:6086-6093.
49. Vogel, S.M., Gao, X., Mehta, D., Ye, R.D., John, T.A., Andrade-Gordon, P., Tiruppathi, C., and Malik, A.B. (2000). Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice. Physiol. Genomics 4:137-145.
50. Wuillemin, W.A., Minnema, M., Meijers, J.C., Roem, D., Eeren-berg, A.J., Nuijens, J.H., ten Cate, H., and Hack, C.E. (1995). Inactivation of factor 11a in human plasma assessed by measuring factor 11a-protease inhibitor complexes: major role for C1-inhibitor. Blood 85:1517-1526.
51. Zeerleder, S., Schloesser, M., Redondo, M., Wuillemin, W.A., Engel, W., Furlan, M., and Lammle, B. (1999). Reevaluation of the incidence of thromboembolic complications in congenital factor 12 deficiency-a study on 73 subjects from 14 Swiss families. Thromb. Haemost. 82:1240-1246.
52. Zhang, H., Lowenberg, E.C., Crosby, J.R., MacLeod, A.R., Zhao, C., Gao, D., Black, C., Revenko, A.S., Meijers, J.C., Stroes, E.S., et al. (2010). Inhibition of the intrinsic coagulation pathway factor 11 by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116:4684-4692.